default author photo

James Jarrett

Gilead Sciences, Inc.

SCHOLARLY PAPERS

2

DOWNLOADS

114

TOTAL CITATIONS

0

Scholarly Papers (2)

Actions:
Email selected abstracts
1.

Modelling the 5-Year Impact of Twice-Yearly Injectable Lenacapavir for HIV Pre-Exposure Prophylaxis in the United States

Number of pages: 21 Posted: 04 Nov 2025
Mia Moore, Serin Lee, Laura Matrajt, Sarah Stansfield, Li Tao, Juan Yang, Dylan Mezzio, James Jarrett, JeanPierre Coaquira Castro, Alice Hsiao, Woodie Zachry and Dobromir Dimitrov
Fred Hutchinson Cancer Research Center, Incheon National University, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center, Gilead Sciences, Inc., Gilead Sciences, Inc., Gilead Sciences, Inc., Gilead Sciences, Inc., Gilead Sciences, Inc., Gilead Sciences, Inc., Gilead Sciences, Inc. and Fred Hutchinson Cancer Research Center
Downloads 75 (844,901)

Abstract:

Loading...

HIV prevention, pre-exposure prophylaxis, lenacapavir, modelling

2.

Clinical Benefits and Cost-Effectiveness of Emergency Department Blood-Borne Virus (BBV) Opt-Out Testing: Advancing Elimination Targets for Viral Hepatitis and HIV Transmission in Australia

Number of pages: 23 Posted: 06 Apr 2026
Joseph S. Doyle, Phillip Keen, Valerie Delpech, Louise Evans, Laurel Bates, Yixuan Ma, Andrea Polokaova, Erik Robinson, Elisabeth J. Adams, James Jarrett and Murad Ruf
Monash University, University of New South Wales (UNSW), UK Health Security Agency, South Western Sydney Local Health District - Liverpool Hospital, Aquarius Population Health Ltd, Aquarius Population Health Ltd, Aquarius Population Health Ltd, Aquarius Population Health Ltd, Aquarius Population Health Ltd, Gilead Sciences, Inc. and Gilead Sciences Europe Ltd
Downloads 39 (1,196,171)

Abstract:

Loading...

blood-borne viruses, hepatitis B, hepatitis C, human immunodeficiency virus, opt-out testing, emergency department, elimination targets